E-NEWS FROM THE NATIONAL VACCINE INFORMATION CENTER

Vienna, Virginia http://www.909shot.com

Journal of American Medical Association article says drug safety studies are inadequate.

++++++++++++++++++++++++++++++++++++++++++++++++++++++++

Conclusions The quality and quantity of safety reporting vary across medical areas, study designs, and settings but they are largely inadequate. Current standards for safety reporting in randomized trials should be revised to address this inadequacy.

JAMA. 2001;285:437-443

http://jama.ama-assn.org/issues/current/abs/joc00579.html

Completeness of Safety Reporting in Randomized Trials - An Evaluation of  7 Medical Areas

John P. A. Ioannidis, MD; Joseph Lau, MD

Context Randomized trials with adequate sample size offer an opportunity to assess the safety of new medications in a controlled setting; however, generalizable data on drug safety reporting are sparse.

Objective To scrutinize the completeness of safety reporting in randomized trials.

Design, Setting, and Patients Survey of safety reporting in 192 randomized drug trials 7 diverse topics with sample sizes of at least 100 patients and at least 50 patients in a study arm (N = 130074 patients). Trial reports were identified from comprehensive meta-analyses in 7 medical areas.

Main Outcome Measures Adequate reporting of specific adverse effects and frequency and reasons for withdrawals due to toxic effects; article space allocated to safety reporting and predictors of such reporting.

Results Severity of clinical adverse effects and laboratory-determined toxicity was adequately defined in only 39% and 29% of trial reports, respectively. Only 46% of trials stated the frequency of specific reasons for discontinuation of study treatment due to toxicity. For these 3 parameters, there was significant heterogeneity in rates of adequate reporting across topics ( P = .003, P<.001, and P = .02, respectively). Overall, the median space allocated to safety results was 0.3 page. A similar amount of space was devoted to contributor names and affiliations ( P = .16). On average, the percentage of space devoted to safety in the results section was 9.3% larger in trials involving dose comparisons than in those that did not ( P<.001) and 3.8% smaller in trials reporting statistically significant results for efficacy outcomes ( P = .047).  Conclusions The quality and quantity of safety reporting vary across medical areas, study designs, and settings but they are largely inadequate. Current standards for safety reporting in randomized trials should be revised to address this inadequacy.

JAMA. 2001;285:437-443

View Full Text

Author/Article Information

1 of 2 01/24/2001 11:11 AM

Completeness of Safety Reporting in...s: An Evaluation of 7 Medical Areas

http://jama.ama-assn.org/issues/current/abs/joc00579.html

News@909shot.com is a free service of the National Vaccine Information

Center and is supported through membership donations.  Learn more about

vaccines, diseases and how to protect your informed

consent rights http://www.909shot.com

Become a member and support NVIC’s work  https://www.909shot.com/order.htm

To sign up for a free e-mail subscription

http://www.909shot.com/emaillist.htm

To unsubscribe from this list, send an email to news-request@909shot.com and type UNSUBSCRIBE in the body of the email.

NVIC is funded through individual membership donations and does not receive government funding. Barbara Loe Fisher, President and Co-founder.

NOTE: This is not an interactive e-mail list. Please do not respond to messages

ALL INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR LEGAL ADVICE.  THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.